- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07398066
DEXmedetomidine voor postoperatieve analgesie en delierpreventie na NEUROchirurgie (DEX-NEURO Trial) (DEX-NEURO)
DEXmedetomidine voor postoperatieve analgesie en deliriumpreventie na NEUROchirurgie: Een dubbelblinde gerandomiseerde placebo-gecontroleerde studie (DEX-NEURO Studie)
Post-craniotomy pain is common and often undertreated. Inadequate analgesia can lead to patient discomfort and higher opioid consumption, which may result in respiratory depression, sedation risks and impaired neurological assessment in the early postoperative period. The incidence of post-operative delirium after intracranial surgery was 19%, ranging from 12 to 26% caused by variation in clinical features and delirium assessment methods1. It is associated with increased morbidity, longer length of hospital stay, and harm to self or staffs.
Dexmedetomidine (Precedex) is a highly selective α2-adrenergic agonist with the properties of analgesia, sedative, anxiolytic and neuroprotection without significant respiratory depression. Most of the trials administered a loading dose of 0.5-1.0 μg/kg intravenous dexmedetomidine over 10 minutes followed by infusion dose 0.2-0.7 μg/kg/hour. The use of intraoperative dexmedetomidine is believed to reduce the usage of postoperative opioids where frequent neurological assessment is often required in neurosurgical patients. Beyond the benefit of analgesia, perioperative dexmedetomidine has been studied for prevention of postoperative delirium. Randomized trials in mixed noncardiac surgical populations reported that low-dose perioperative dexmedetomidine may reduce the incidence of delirium. Dexmedetomidine produces dose-dependent bradycardia and hypotension, which should be carefully monitored to maintain the cerebral perfusion pressure in brain surgery. However, most trials and meta-analyses have focused on general surgical or cardiac cohorts; the evidence remains limited in neurosurgical (craniotomy) patients.
Although it showed promising benefits of analgesia and neuroprotection in non-neurosurgical patients, recent meta-analyses of intraoperative dexmedetomidine reported high degree of heterogeneity due to the inclusion of varied procedures (elective vs emergent craniotomy), dosing regimes (loading dose only versus loading dose + infusion versus infusion only) and varied primary endpoints (postoperative pain scores, cumulative opioid consumption or incidence of delirium). Therefore, this randomized, double-blind, placebo-controlled trial is designed to examine the use of intravenous dexmedetomidine in the reduction of postoperative pain score and delirium in neurosurgical patients. We hypothesised that intravenous dexmedetomidine reduces postoperative pain score and delirium with lower need of rescue analgesia and amount of morphine consumption in patients undergoing craniotomy.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
There are several similar studies been conducted in the literature search. However, the majority of the studies focus on the intensive care unit patient or non-neurosurgery patients. It is believed that intravenous dexmedetomidine can reduce the postoperative pain score with lesser need for rescue analgesia and morphine consumption to facilitate postoperative neurological assessment.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Ka Ting Dr Ng, MBChB
- Telefoonnummer: +60379492411
- E-mail: katingng1@gmail.com
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- All adult (American Society of Anaesthesiologists (ASA 1-2) who >18 years old and <65 years old undergoing elective craniotomy
Exclusion Criteria:
- Patients who are ASA 3-5 or BMI <18/ >40 or allergic to dexmedetomidine will be excluded. Patients with high-grade heart block or uncontrolled bradyarrhythmia will also be excluded.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Intravenous dexmedetomidine
Intravenous dexmedetomidine loading dose 0.5mcg/kg followed by 0.5mcg/kg/hour |
intravenous dexmedetomidine loading dose 0.5mcg/kg followed by 0.5mcg/kg/hour
Andere namen:
|
|
Placebo-vergelijker: Intravenous normal saline
intravenous normal saline loading and infusion dose |
Intravenous normal saline loading and infusion dose of normal saline |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Postoperative pain score at recovery area
Tijdsspanne: In the recovery area after pushing out from the operation theatre (Post-operative 1-hour, Day 1, Day 2)
|
Numerical Rating Scale (0 no pain-10 most pain) |
In the recovery area after pushing out from the operation theatre (Post-operative 1-hour, Day 1, Day 2)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Need of rescue analgesia
Tijdsspanne: In the recovery area after pushing out from operation theatre (Post-operative 1-hour)
|
Need to receive additional analgesia (bolus of ketamine, fentanyl, morphine) in the recovery area |
In the recovery area after pushing out from operation theatre (Post-operative 1-hour)
|
|
Total usage of postoperative morphine use in the first 24-hour
Tijdsspanne: In the first 24-hour after surgery in neurointensive care unit
|
The amount of morphine usage in milligram |
In the first 24-hour after surgery in neurointensive care unit
|
|
Postoperative nausea or vomiting
Tijdsspanne: Within the first 24-hour in neurointensive care unit
|
Incidence of nausea or vomiting in the first 24-hour in neurointensive care unit |
Within the first 24-hour in neurointensive care unit
|
|
Incidence of delirium
Tijdsspanne: Day-1 and Day-2 in neurointensive care unit
|
Assessed by CAM-ICU scoring test |
Day-1 and Day-2 in neurointensive care unit
|
|
Patient satisfaction scale of analgesia control
Tijdsspanne: Day-1 in neurointensive care unit
|
Numerical rating scale (0 not satisfy - 10 very satisfy) |
Day-1 in neurointensive care unit
|
|
Adverse events of dexmedetomidine (hypotension and bradycardia).
Tijdsspanne: During surgery when intravenous dexmedetomidine is started
|
systolic blood pressure < 90, heart rate <60 |
During surgery when intravenous dexmedetomidine is started
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet. 2016 Oct 15;388(10054):1893-1902. doi: 10.1016/S0140-6736(16)30580-3. Epub 2016 Aug 16.
- Li X, Yang J, Nie XL, Zhang Y, Li XY, Li LH, Wang DX, Ma D. Impact of dexmedetomidine on the incidence of delirium in elderly patients after cardiac surgery: A randomized controlled trial. PLoS One. 2017 Feb 9;12(2):e0170757. doi: 10.1371/journal.pone.0170757. eCollection 2017.
- Zhao LH, Shi ZH, Chen GQ, Yin NN, Chen H, Yuan Y, Cao W, Xu M, Hao JJ, Zhou JX. Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients With Delayed Extubation After Craniotomy: A Randomized Controlled Trial. J Neurosurg Anesthesiol. 2017 Apr;29(2):132-139. doi: 10.1097/ANA.0000000000000260.
- Bielka K, Kuchyn I, Babych V, Martycshenko K, Inozemtsev O. Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic small es, Cyrillicholecystectomy: a randomized controlled study. BMC Anesthesiol. 2018 Apr 20;18(1):44. doi: 10.1186/s12871-018-0508-6.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neurologische manifestaties
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Psychische aandoening
- Neoplasmata per site
- Neoplasmata
- Neoplasmata per histologisch type
- Verwardheid
- Neurologische gedragsmanifestaties
- Neurocognitieve stoornissen
- Neoplasmata, zenuwweefsel
- Neoplasmata van het zenuwstelsel
- Neoplasmata, vaatweefsel
- Meningeale neoplasmata
- Neoplasmata van het centrale zenuwstelsel
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Pijn
- Delirium
- Meningeoom
- Hersenneoplasmata
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Farmaceutische voorbereidingen
- Azoles
- Imidazolen
- Crystalloid -oplossingen
- Isotone oplossingen
- Oplossingen
- Dexmedetomidine
- Zoutoplossing
Andere studie-ID-nummers
- 16023
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .